CSIMarket
 


Macrogenics Inc   (MGNX)
Other Ticker:  
 
 

MGNX's Income from Cont. Operations Growth by Quarter and Year

Macrogenics Inc 's Income from Cont. Operations results by quarter and year




MGNX Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December -46.07 12.80 -58.02 -2.09
III Quarter September 17.55 -24.81 -52.89 -36.04
II Quarter June 57.47 -41.30 -39.94 -46.89
I Quarter March -38.01 -66.44 -51.27 -44.72
FY   -9.06 -119.75 -202.12 -129.74



MGNX Income from Cont. Operations fourth quarter 2023 Y/Y Growth Comment
Macrogenics Inc in the fourth quarter 2023 recorded loss from continued operations of $ -46.07 millions.

According to the results reported in the fourth quarter 2023, Macrogenics Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Macrogenics Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. 27 in the fourth quarter 2023.




MGNX Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Macrogenics Inc 's fourth quarter 2023 Income from Cont. Operations $ -46.07 millions MGNX's Income Statement
Macrogenics Inc 's fourth quarter 2022 Income from Cont. Operations $ 12.80 millions Quarterly MGNX's Income Statement
New: More MGNX's historic Income from Cont. Operations Growth >>


MGNX Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September -69.46 % - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #3
Overall #27

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
-98.11 % -12430.62 % -45205.6 %
(June 30. 2015)   (March 31, 2016)
Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #3
Overall #27
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
-98.11 % -12430.62 % -45205.6 %
(June 30. 2015)   (March 31, 2016)

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Macrogenics Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MGNX's IV. Quarter Q/Q Income from Cont. Operations Comment
Current loss from continued operations of -46.07 millions by Macrogenics Inc come out even worse if you take a look at 17.55 millions in the third quarter.

Within Major Pharmaceutical Preparations industry Macrogenics Inc achieved highest sequential Income from Cont. Operations growth. While Macrogenics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MGNX's IV. Quarter Q/Q Income from Cont. Operations Comment
IV. Quarter 2023 results of -46.07 millions by Macrogenics Inc come out even worse compare to the 17.55 millions loss from continued operations in the previous quarter.

Within Major Pharmaceutical Preparations industry Macrogenics Inc achieved highest sequential Income from Cont. Operations growth. While Macrogenics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Macrogenics Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -9.06 $ 49.82 $ 7.45 $ -91.32 $ -119.76
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - 568.76 % - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # 27 # 34 # 0 # 0 # 0




Cumulative Income from Cont. Operations growth Comment


Macrogenics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
-98.11 %
-12430.62 %
-45205.6 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 3
S&P 500 # 27
Cumulative Income from Cont. Operations growth Comment


Macrogenics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
-98.11 %
-12430.62 %
-45205.6 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 3
S&P 500 # 27




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
MGNX's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for MGNX's Competitors
Income from Cont. Operations Growth for Macrogenics Inc 's Suppliers
Income from Cont. Operations Growth for MGNX's Customers

You may also want to know
MGNX's Annual Growth Rates MGNX's Profitability Ratios MGNX's Asset Turnover Ratio MGNX's Dividend Growth
MGNX's Roe MGNX's Valuation Ratios MGNX's Financial Strength Ratios MGNX's Dividend Payout Ratio
MGNX's Roa MGNX's Inventory Turnover Ratio MGNX's Growth Rates MGNX's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Dec 31 2023
Charles River Laboratories International inc -0.08%$ -0.081 millions
Sanuwave Health Inc -0.23%$ -0.232 millions
Regeneron Pharmaceuticals Inc -3.13%$ -3.133 millions
Haemonetics Corporation-5.17%$ -5.169 millions
Resmed Inc -7.16%$ -7.165 millions
Edwards Lifesciences Corporation-7.20%$ -7.204 millions
Bristol myers Squibb Company-12.99%$ -12.988 millions
Gilead Sciences Inc -13.23%$ -13.227 millions
Utah Medical Products Inc-13.50%$ -13.499 millions
Alpha Tau Medical Ltd -13.64%$ -13.640 millions
Masimo Corp-17.13%$ -17.125 millions
Merit Medical Systems Inc-17.28%$ -17.281 millions
Fresenius Medical Care Ag-18.10%$ -18.099 millions
Qiagen N v -19.35%$ -19.354 millions
Star Equity Holdings Inc -27.24%$ -27.239 millions
Mettler toledo International Inc -30.49%$ -30.485 millions
Avantor Inc -30.49%$ -30.487 millions
Sanofi-35.93%$ -35.926 millions
Icu Medical Inc-38.15%$ -38.151 millions
Amedisys Inc -39.71%$ -39.707 millions
Embecta Corp -42.90%$ -42.898 millions
Pro dex Inc -43.12%$ -43.117 millions
Becton Dickinson And Company-44.79%$ -44.794 millions
Bio techne Corp-45.08%$ -45.075 millions
Harmony Biosciences Holdings inc -45.15%$ -45.150 millions
Exagen Inc -45.72%$ -45.721 millions
Amgen Inc -52.54%$ -52.537 millions
Biogen Inc -54.70%$ -54.704 millions
Taro Pharmaceutical Industries Ltd-56.33%$ -56.330 millions
Bio rad Laboratories Inc -58.04%$ -58.043 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com